AU650065B2 - Inhibitor of lymphocyte response and immune-related disease - Google Patents

Inhibitor of lymphocyte response and immune-related disease Download PDF

Info

Publication number
AU650065B2
AU650065B2 AU87559/91A AU8755991A AU650065B2 AU 650065 B2 AU650065 B2 AU 650065B2 AU 87559/91 A AU87559/91 A AU 87559/91A AU 8755991 A AU8755991 A AU 8755991A AU 650065 B2 AU650065 B2 AU 650065B2
Authority
AU
Australia
Prior art keywords
peptide
amino acid
peptides
cells
arthritis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
AU87559/91A
Other languages
English (en)
Other versions
AU8755991A (en
Inventor
Claire J.P. Boog
Irun R. Cohen
Ruurd Van Der Zee
Willem Van Eden
Marca H.M. Wauben
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Nederlanden Staat
Universiteit Utrecht
Original Assignee
Yeda Research and Development Co Ltd
Nederlanden Staat
Rijksuniversiteit Utrecht
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd, Nederlanden Staat, Rijksuniversiteit Utrecht filed Critical Yeda Research and Development Co Ltd
Publication of AU8755991A publication Critical patent/AU8755991A/en
Application granted granted Critical
Publication of AU650065B2 publication Critical patent/AU650065B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU87559/91A 1990-09-06 1991-09-05 Inhibitor of lymphocyte response and immune-related disease Expired - Fee Related AU650065B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57850690A 1990-09-06 1990-09-06
US578506 1990-09-06
PCT/US1991/006434 WO1992004049A1 (en) 1990-09-06 1991-09-05 Inhibitor of lymphocyte response and immune-related disease

Publications (2)

Publication Number Publication Date
AU8755991A AU8755991A (en) 1992-03-30
AU650065B2 true AU650065B2 (en) 1994-06-09

Family

ID=24313172

Family Applications (1)

Application Number Title Priority Date Filing Date
AU87559/91A Expired - Fee Related AU650065B2 (en) 1990-09-06 1991-09-05 Inhibitor of lymphocyte response and immune-related disease

Country Status (8)

Country Link
EP (1) EP0503055A1 (cg-RX-API-DMAC7.html)
JP (1) JPH05507501A (cg-RX-API-DMAC7.html)
AU (1) AU650065B2 (cg-RX-API-DMAC7.html)
CA (1) CA2071896A1 (cg-RX-API-DMAC7.html)
IL (1) IL99429A0 (cg-RX-API-DMAC7.html)
NZ (1) NZ239699A (cg-RX-API-DMAC7.html)
WO (1) WO1992004049A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA917097B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09509135A (ja) * 1993-06-02 1997-09-16 ティーヴィダブリュー テレソン インスティテュート フォー チャイルド ヘルス リサーチ 免疫寛容の誘導における利用のためのクリプティックペプチド
ES2216009T3 (es) * 1994-03-21 2004-10-16 Rijksuniversiteit Utrecht Fragmentos peptidicos de proteinas de estres microbianas y composicion farmaceutica a base de estos para el tratamiento y la prevencion de enfermedades inflamatorias.
GB9419553D0 (en) * 1994-09-27 1994-11-16 Univ Bristol Polypeptides and their use in the treatment of auto-immune disease
IT1271074B (it) * 1994-11-21 1997-05-26 Italfarmaco Spa Peptidi ad attivita' antiinfiammatoria
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6338852B1 (en) 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US5993803A (en) * 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
EP0994717A4 (en) * 1997-01-24 2000-07-26 Autoimmune Inc TREATING AUTOIMMUNE DISEASES BY TOLERANCE INCREASED BY COMBINING WITH METHOTREXATE
US6465633B1 (en) 1998-12-24 2002-10-15 Corixa Corporation Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
EP2157101B1 (en) 2002-01-31 2014-09-24 Andromeda Bio Tech Ltd. HSP peptides and analogs for modulation of immune responses via antigen presenting cells
EP1575526B1 (en) 2002-05-21 2012-06-06 Irun R. Cohen Dna vaccines encoding heat shock proteins
US8691772B2 (en) 2005-01-04 2014-04-08 Yeda Research And Development Co. Ltd. HSP60, HSP60 peptides and T cell vaccines for immunomodulation

Also Published As

Publication number Publication date
CA2071896A1 (en) 1992-03-07
EP0503055A4 (cg-RX-API-DMAC7.html) 1994-02-16
JPH05507501A (ja) 1993-10-28
IL99429A0 (en) 1992-08-18
WO1992004049A1 (en) 1992-03-19
EP0503055A1 (en) 1992-09-16
ZA917097B (en) 1992-09-30
AU8755991A (en) 1992-03-30
NZ239699A (en) 1993-11-25

Similar Documents

Publication Publication Date Title
Wauben et al. Disease inhibition by major histocompatibility complex binding peptide analogues of disease-associated epitopes: more than blocking alone.
Anderton et al. Activation of T cells recognizing self 60-kD heat shock protein can protect against experimental arthritis.
Sakai et al. Prevention of experimental encephalomyelitis with peptides that block interaction of T cells with major histocompatibility complex proteins.
US8343500B2 (en) Peptide composition
JP2635444B2 (ja) 自己抗体の経口投与による自己免疫性疾患の治療
EP0359783B1 (en) Treatment of autoimmune diseases by oral administration of autoantigens
AU650065B2 (en) Inhibitor of lymphocyte response and immune-related disease
Hu et al. Experimental mucosal induction of uveitis with the 60‐kDa heat shock protein‐derived peptide 336–351
KR100216097B1 (ko) 자가면역 및 악성종양질환 치료제로서의 t세포 수용체 펩티드
Wraith et al. Cross-reactive antigen recognition by an encephalitogenic T cell receptor. Implications for T cell biology and autoimmunity.
EP0751957B1 (en) Peptide fragments of microbial stress proteins and pharmaceutical composition made thereof for the treatment and prevention of inflammatory diseases
Ragno et al. A synthetic 10-kD heat shock protein (hsp10) from Mycobacterium tuberculosis modulates adjuvant arthritis
Yang et al. Prevention of adjuvant arthritis in rats by a nonapeptide from the 65-kD mycobacterial heat-shock protein
Steinman The development of rational strategies for selective immunotherapy against autoimmune demyelinating disease
WO2005087261A2 (en) Identification of self and non-self antigens implicated in autoimmune diseases
Deane et al. Identification and characterization of a DR4‐restricted T cell epitope within chlamydia heat shock protein 60
Spack et al. Induction of tolerance in experimental autoimmune myasthenia gravis with solubilized MHC class II: acetylcholine receptor peptide complexes
HU224160B1 (hu) P277 Peptidanalógok, ezek alkalmazása a diabétesz in vitro diagnosztizálására szolgáló gyógyszerkészítmények előállítására, gyógyszerkészítmények és diagnosztikus kit
CA2920321A1 (en) Peptides derived from thyroid stimulating hormone receptor useful in the prevention and/or treatment of graves' disease
MXPA04007510A (es) Peptidos tolerogenicos de la proteina basica de mielina.
NO308611B1 (no) AnalogifremgangsmÕte for fremstilling av et terapeutisk aktivt peptid
HU219306B (en) T-cell-suppressive peptide fragments of human myelin basic protein (hmbp) and pharmaceutical compositions containing them
EP1945246A2 (en) Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
Protti et al. Myasthenia gravis. T epitopes on the delta subunit of human muscle acetylcholine receptor
Vandenbark et al. Determinants of human myelin basic protein that induce encephalitogenic T cells in Lewis rats.